318
Views
23
CrossRef citations to date
0
Altmetric
Original Articles

Comparison of the Treatment Results for Behçet Uveitis in Patients Treated with Infliximab and Interferon

&
Pages 305-314 | Received 31 Oct 2018, Accepted 08 Apr 2019, Published online: 03 Jul 2019
 

ABSTRACT

Purpose: To compare the efficacy and safety of infliximab and interferon in patients with refractory Behçet uveitis.

Methods: Medical records of 20 patients treated with infliximab (IFX) and 33 patients treated with interferon (IFN) were retrospectively analyzed by evaluating the number of uveitis attacks, visual acuity and ocular inflammation at 6 and 12 months after initiation of treatment.

Results: Mean duration of treatment was 22 ± 18 months in IFX group and 30.3 ± 22.5 months in IFN group. Sixteen patients of IFX group (80%) and 28 patients of IFN group (85%) achieved remission. In both groups, the mean best-corrected visual acuity and all inflammatory parameters improved. In terms of these parameters, there was no significant difference between the two groups.

Conclusion: Infliximab and interferon improve control of ocular inflammation and efficiently decrease the relapse rate. Our results determined no significant difference between two agents in controlling intraocular inflammation.

Declaration Of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.